Scleroderma Clinical Trials Consortium Inc
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2020 | 222,811 | 168,700 | 54,111 | 166.5 | 0% |
| 2021 | 197,214 | 95,927 | 101,287 | 305.5 | 0% |
| 2022 | 271,981 | 177,441 | 94,540 | 171.5 | 0% |
| 2023 | 264,484 | 210,242 | 54,242 | 147.9 | 0% |
In its most recent public year (2023), this organization brought in $54,242 more than it spent. Its reserves stood at about 147.9 months of spending, down from 166.5 in 2020. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
A new entry when its next filing is released. No account, no email; works in any feed reader, Slack, or automation tool. How following works